Corrado Amato

Corrado Amato

Auto-generated profile, based on publicly available information

Corrado Amato

Department of Health Promotion and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2015 in Clinical Hemorheology and Microcirculation
Verified
Journal Article
Open access
GCGregorio Caimi
Gregorio Caimi
FFF. Ferrara
F. Ferrara
MMM. Montana
M. Montana
IMI. Muratori
I. Muratori
CAC. Amato
C. Amato
EHE. Hopps
E. Hopps
Venous leg ulcers are common in subjects with chronic venous insufficiency. The increased intraluminal pressure causes alteration of the skin microcirculation, leukocyte activation and release of proteolytic enzymes leading to ulceration. An impaired expression and activity of matrix metalloproteases (MMPs) and their tissue inhibitors (TIMPs) might influence extracellular matrix degradation and deposition in chronic venous ulcers with the failure of the healing process. Our aim was to evaluate plasma concentration of gelatinases (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in subjects with venous leg ulcers before and after the compression therapy. We enrolled 36 subjects (12 men and 24 women, mean age 67.38 ± 12.7 yrs) with non-infected venous leg ulcers (CEAP C6), which underwent a color Duplex scan examination of the veins and arteries of the inferior limbs and were treated with a multi-layer bandaging system. The ulcer healing was obtained in 23 subjects only (9 men and 14 women). We evaluated, on fasting venous blood, the plasma levels of MMP-2, MMP-9, TIMP-1 and TIMP-2 using ELISA kit, before and after the treatment. We observed a significant increase in plasma concentration of gelatinases and their inhibitors and in MMP-2/TIMP-2 ratio in subjects with leg ulcers in comparison with normal controls. In subjects with healed ulcers we found a decrease in MMP-9 and TIMP-1 levels and in MMP-2/TIMP-2 ratio compared to the baseline values, although higher levels of all the examined parameters in comparison with normal controls. In conclusion, plasma MMPs profile is impaired in subjects with venous leg ulcers and it improves after the healing, persisting anyway altered in respect to healthy controls.

19 September 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
IMIda Maria Muratori
Ida Maria Muratori
FCFrancesco Contorno
Francesco Contorno
CACorrado Amato
Corrado Amato
Introduction The progression of chronic venous disease (CVD) is characterized by edema of the legs and/or venous ulcers of the lower limbs in association with cutaneous signs and/or skin alterations, such as hyperpigmentation, corona phlebectatica, telangiectasia, eczematous dermatitis, lipodermatosclerosis, atrophie blanche, cellulitis, and induration. Xioglican cream is a galactosaminoglycan polysulfate and hyaluronic acid-containing medical device with strong hydrophilic, moisturizing, and soothing properties. This post-marketing observational study evaluated topical Xioglican cream in the amelioration of skin manifestations and clinical signs and symptoms in patients with CVD treated in routine clinical practice. Methods Adult patients (18–75 years) with a clinical diagnosis of C2–C3 CVD according to Clinical, Etiology, Anatomy, and Pathophysiology (CEAP) classification who received 12 weeks of treatment with Xioglican (applied up to 3 times daily), according to investigator decision (and consistent with conventional clinical practice and established standard of care), were enrolled from two study sites in Italy. A range of endpoints were used to evaluate efficacy, safety, effect on patient quality of life (QoL), and patient satisfaction with topical application of Xioglican cream in the physiological restoration of skin signs and symptoms. Results In patients with CVD (n = 30), Xioglican cream reduced CVD-related skin manifestations and associated symptoms, with significant reductions in leg circumference [mean ± standard deviation (SD): − 3.21 ± 3.39 cm for left and − 2.92 ± 2.70 cm for right legs, both p < 0.0001] and local edema (− 5.52 ± 7.94 cm, p = 0.0034) and significant improvement in Venous Clinical Severity Scores (mean 0.52 ± 1.94 decrease from baseline, p = 0.1952) observed after 12 weeks. Skin burning, pain, aching or tiredness, and QoL were also significantly improved. There was no change in CEAP classification. Globally, 92.0% of patients were “Very satisfied” or “Satisfied” with the product. Conclusions Topical treatment with Xioglican cream improves the signs, symptoms, and QoL of patients with CVD class C2–C3.

30 May 2025 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
PSPaolo Santini
Paolo Santini
WMWalter Marrocco
Walter Marrocco
GMGianmarco Marrocco
Gianmarco Marrocco
AFAmalia Lucia Fazzari
Amalia Lucia Fazzari
CACorrado Amato
Corrado Amato
RMromeo martini
romeo martini